STOCK TITAN

Vanguard disaggregation: Eli Lilly (NYSE: LLY) ownership shows 0 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Eli Lilly & Co — Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned of Eli Lilly common stock, representing 0% of the class, following an internal realignment effective January 12, 2026. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; this amendment shows no reported beneficial ownership in LLY.

The filing records 0 shares and 0% ownership and explains an internal realignment on January 12, 2026 that caused subsidiaries to report separately in reliance on SEC Release No. 34-39538. This is an administrative disclosure describing reporting structure rather than a trading event.

Cash‑flow treatment or subsidiary-level share counts are not provided in this excerpt; subsequent filings by Vanguard subsidiaries may show holdings under their own names.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

Does The Vanguard Group own any Eli Lilly (LLY) shares in this amendment?

No. The filing states 0 shares beneficially owned, equal to 0% of the class. It explains Vanguard underwent an internal realignment effective January 12, 2026, after which subsidiaries report separately.

Why does the Schedule 13G/A show zero ownership for Vanguard in LLY?

Because Vanguard reorganized on January 12, 2026 and, per SEC Release No. 34-39538, certain subsidiaries now report holdings separately. The filing attributes the zero to that disaggregation, not necessarily to divestment.

Who signed the amendment for The Vanguard Group on this filing?

Ashley Grim, titled Head of Global Fund Administration, signed the amendment and dated the signature 03/26/2026. The filing lists Vanguard's Malvern, PA address at 100 Vanguard Blvd.

Does this Schedule 13G/A disclose subsidiary-level share counts for LLY?

No. The amendment explains subsidiaries will report separately but does not include their individual share counts in this excerpt. It states the subsidiaries pursue the same investment strategies as before the realignment.
Lilly Eli & Co

NYSE:LLY

View LLY Stock Overview

LLY Rankings

LLY Latest News

LLY Latest SEC Filings

LLY Stock Data

806.39B
940.96M
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS